22 completed, 10 unknown, 2 terminated, 1 approved for marketing. 12 Phase 2, 12 Phase 3, 6 Phase 4, 5 Phase 1, 4 Not applicable.
Follow Uremic Pruritus: new trials by email Literature Review of Uremic Pruritus trials Research Report on Uremic Pruritus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritus. Probiotic Blend Capsule, Activated Charcoal - Chronic Kidney Disease, Uremic Pruritus | Phase 2 | Unknown | Ain Shams University | 123 | 2024-09-01 | 2024-08-30 |
| Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis Fexofenadine, Gabapentin - Uremic Pruritus, Chronic Kidney Disease-associated Pruritus | Phase 4 | Completed | Tanta University | 60 | 2024-07-01 | 2025-04-27 |
| Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus QLG2198, Placebo - Uremic Pruritus | Phase 3 | Unknown | Qilu Pharmaceutical (Hainan) Co., Ltd. | 194 | 2024-06-18 | 2024-06-21 |
| The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus Hemp, Placebo - Uremic Pruritus | Phase 1 / Phase 2 | Completed | Thammasat University Hospital | 60 | 2023-09-15 | 2024-03-27 |
| Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus Difelikefalin Injection, Placebo Injection - Uremic Pruritus | Phase 3 | Completed | Vifor Fresenius Medical Care Renal Pharma | 260 | 2023-05-18 | 2025-09-12 |
| A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus Thalidomide, Placebo - Haemodialysis, Uremic Pruritus | Phase 4 | Unknown | RenJi Hospital | 40 | 2022-09-15 | 2022-09-01 |
| Using of Extra Virgin Olive Oil in Hemodialysis Patients to Improve Pruritus and Sleep Disorders Olive oil application in hemodialysis patients with pruritus, Normal saline application in hemodialysis patients with pruritus - Uremic Pruritus | Not applicable | Unknown | National Taipei University of Nursing and Health Sciences | 86 | 2022-08-01 | 2022-07-20 |
| Acupressure on Uremic Pruritus and Sleep Quality Among Patients Receiving Hemodialysis Acupressure - Hemodialysis, Uremic Pruritus | Not applicable | Completed | National Taipei University of Nursing and Health Sciences | 44 | 2021-03-15 | 2023-03-23 |
| A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. MR13A9, Placebo - Uremic Pruritus | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 178 | 2021-01-16 | 2025-09-10 |
| The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin, Placebo - Uremic Pruritus | Early Phase 1 | Unknown | Chang Gung Memorial Hospital | 60 | 2020-12-01 | 2020-12-03 |
| A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet Nalfurafine Hydrochloride, Nalfurafine Hydrochloride+Placebo, Placebo - Uremic Pruritus | Phase 3 | Unknown | Shenyang Sunshine Pharmaceutical Co., LTD. | 135 | 2020-09-07 | 2021-01-28 |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis Stage I:HSK21542 0.05 μg/kg, Stage I:HSK21542 0.15 μg/kg, Stage I:HSK21542 0.30 μg/kg - Uremic Pruritus | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 131 | 2020-08-10 | 2022-08-09 |
| AST-120 in Hemodialysis Patients With Uremic Pruritus AST-120 - Uremic Pruritus | Phase 4 | Completed | Conmed Pharmaceutical & Bio-Medical Corporation | 100 | 2020-07-02 | 2023-09-07 |
| Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients LT5001, Placebo - Uremic Pruritus | Phase 1 / Phase 2 | Terminated | Lumosa Therapeutics Co., Ltd. | 18 | 2020-05-14 | 2026-02-10 |
| CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus CR845 0.5 mcg/kg - Uremic Pruritus | Phase 3 | Completed | Cara Therapeutics, Inc. | 222 | 2019-05-06 | 2021-10-15 |
| A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. MR13A9, Placebo - Uremic Pruritus | Phase 2 | Completed | Kissei Pharmaceutical Co., Ltd. | 247 | 2019-02-01 | 2025-12-05 |
| CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus CR845 0.5 mcg/kg, Placebo - Uremic Pruritus | Phase 3 | Completed | Cara Therapeutics, Inc. | 473 | 2018-07-17 | 2022-04-26 |
| Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus Doxepin, Gabapentin - Uremic Pruritus | Phase 4 | Completed | University of Balamand | 14 | 2018-06-01 | 2018-11-29 |
| Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients PG102P, Placebo - Uremic Pruritus | Not applicable | Completed | Seoul National University Boramae Hospital | 80 | 2018-05-01 | 2019-09-19 |
| A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) CR845 0.5 mcg/kg, Placebo - Uremic Pruritus | Phase 3 | Completed | Cara Therapeutics, Inc. | 378 | 2018-02-20 | 2022-04-26 |
Showing 20 of 35. Sign in to see all of them.
Pruritus (13) · Kidney Failure, Chronic (8) · Renal Insufficiency, Chronic (6) · Anthrax (1) · Sleep Initiation and Maintenance Disorders (1) · Sleep Wake Disorders (1) · Uremia (1)
Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (13) · Skin Diseases (13) · Skin Manifestations (13) · Skin and Connective Tissue Diseases (13) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Kidney Diseases (10) · Male Urogenital Diseases (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Chronic Disease (9) · Disease Attributes (9) · Pathologic Processes (9) · Renal Insufficiency (9)
difelikefalin (5) · Gabapentin (2) · Nalbuphine (2) · Pregabalin (2) · TRK 820 (2) · fexofenadine (2) · AST 120 (1) · Acupressure (1) · BID protein, human (1) · Charcoal (1) · Doxepin (1) · Sugars (1) · Thalidomide (1)
Cara Therapeutics, Inc. (7) · Trevi Therapeutics (3) · Kissei Pharmaceutical Co., Ltd. (2) · National Taipei University of Nursing and Health Sciences (2) · National Taiwan University Hospital (2) · Toray Industries, Inc (2) · Acologix, Inc. (1) · Ain Shams University (1) · Assaf-Harofeh Medical Center (1) · Chang Gung Memorial Hospital (1) · Conmed Pharmaceutical & Bio-Medical Corporation (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Lumosa Therapeutics Co., Ltd. (1) · Patara Pharma (1) · Qilu Pharmaceutical (Hainan) Co., Ltd. (1)
United States (10) · Taiwan (6) · China (4) · Poland (3) · Czechia (2) · Germany (2) · Hungary (2) · Japan (2) · South Korea (2) · Australia (1) · Bulgaria (1) · Canada (1) · Egypt (1) · Israel (1) · Lebanon (1)
Frederique Menzaghi, PhD (2) · Ahmed M Hussein, PhD (1) · Aliaa Mohamed (1) · Chia-Chao Wu, Dr. (1) · Chun Soo Lim, MD, PhD (1) · Frederique Menzaghi (1) · Hsien-Yi Chiu, MD (1) · Jian-Lin Lu, Dr. (1) · June Kuo (1) · Kuo-Cheng Lu, Dr. (1) · Lin-Kuo Ko, Dr. (1) · Mei-Ju Ko, MD (1) · Milica Enoiu, PhD (1)
PMID 33283264, PMID 36039153, PMID 37968132, PMID 39037824, PMID 36016762, PMID 21668425, PMID 30975656, PMID 31702883, PMID 31779697, PMID 35511180, PMID 36185706, PMID 36680419, PMID 37876731, PMID 38196014, PMID 38320524, PMID 39328960, PMID 39402448